A patient on a heparin infusion has an aPTT of 90 and is showing signs of excessive bleeding. What prescription will the nurse anticipate administering?

Choice A reason: The 1 to 5 mcg/mL range is too low for theophylline’s therapeutic effect. Theophylline, a methylxanthine, requires 10-20 mcg/mL to achieve bronchodilation by inhibiting phosphodiesterase and increasing cyclic AMP. Levels below this range are ineffective for asthma or COPD management, risking suboptimal control.

Choice B reason: The 30 to 40 mcg/mL range is toxic for theophylline. Levels above 20 mcg/mL can cause serious side effects like seizures, arrhythmias, or nausea due to its narrow therapeutic index. Therapeutic monitoring ensures levels stay within 10-20 mcg/mL for safe and effective bronchodilation.

Choice C reason: The 50 to 60 mcg/mL range is far above theophylline’s therapeutic range, leading to severe toxicity, including life-threatening arrhythmias or convulsions. Theophylline’s efficacy for airway relaxation occurs at 10-20 mcg/mL, and such high levels are dangerous, requiring immediate intervention to reduce toxicity risks.

Choice D reason: The 10 to 20 mcg/mL range is the targeted therapeutic range for theophylline in adults. Within this range, theophylline inhibits phosphodiesterase, increasing cyclic AMP, promoting bronchodilation, and relieving asthma or COPD symptoms. Monitoring ensures efficacy while minimizing toxicity risks like tachycardia or seizures.

Choice A reason: Drowsiness is not a common adverse effect of chloroquine, an antimalarial drug. Chloroquine inhibits heme polymerization in Plasmodium, with side effects like visual disturbances or dizziness. Drowsiness is more associated with antihistamines or CNS depressants, not chloroquine’s mechanism or pharmacokinetic profile.

Choice B reason: Constipation is not a typical side effect of chloroquine. Its primary adverse effects include gastrointestinal upset, visual toxicity, or neurological symptoms like dizziness. Chloroquine’s action on parasitic metabolism does not significantly affect gastrointestinal motility, making constipation an unlikely reaction to report.

Choice C reason: Dizziness is a known adverse effect of chloroquine, potentially due to its effects on the central nervous system or ototoxicity. Patients should report dizziness, as it may indicate toxicity or neurological involvement, requiring dose adjustment or monitoring to ensure safe antimalarial or anti-inflammatory therapy.

Choice D reason: Insomnia is not a primary adverse effect of chloroquine. While neurological effects like headache or dizziness may occur, insomnia is less common. Chloroquine’s toxicity profile focuses on visual, cardiac, or neurological symptoms, and insomnia is not typically reported, making this less critical to monitor.